GEN Exclusives

More »

GEN News Highlights

More »
Jan 30, 2008

Plexer to Evaluate Auguron’s Technology as Content Source for Its Proteomics Array

  • Plexera Bioscience gained exclusive rights to use Auguron Biosciences’ nucleic acid programmable protein array (NAPPA) technology on its Kx™ Arrays.

    The NAPPA platform enables fresh, functional proteins to be generated on high-density microchips from surface-printed DNA. The Kx Arrays are designed to interrogate interactions of every element simultaneously without the use of labels.

    The option agreement provides Plexera one-year access with the ability to extend the agreement by another year. Plexera will test and develop NAPPA as a content source for Kx in collaboration with Auguron and other partners. At any time during the period, Plexera may exercise the option to negotiate an exclusive license to NAPPA within the field of use of surface plasmon resonance , the detection method used in their platform. 

    “Empowering Plexera’s Kx Array platform with NAPPA will provide access to a virtually unlimited source of protein content with high levels of control over both composition and functionality,” said Jim Richey, cofounder and CEO of Auguron. “By printing DNA and expressing proteins in situ, NAPPA skips the expense-, time-, yield-, and activity-consuming steps associated with conventional printed protein arrays.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?